Erratum to: Cancer Microenvironment
DOI 10.1007/s12307-014-0161-7
The original publication of this article (10.1007/s12307-014-0161-7) unfortunately contained an error. Figures 1 and 2 are the same, the correct figures are presented here.
Study design including the main inclusion and exclusion criteria. ECOG Eastern cooperative oncology group performance status, CRPC Castration-resistant prostate cancer, PSA Prostate-specific antigen, AE Adverse event, SAE Serious adverse event
Proportion of patients discontinuing study drug. One patient is still ongoing (at the time of manuscript submission Oct 2014). Pts Patients, PSA Prostate-specific antigen
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s12307-014-0161-7.
Rights and permissions
About this article
Cite this article
Vogelhuber, M., Feyerabend, S., Stenzl, A. et al. Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan. Cancer Microenvironment 8, 43–44 (2015). https://doi.org/10.1007/s12307-015-0165-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12307-015-0165-y